Transatlantique Private Wealth LLC lowered its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 18.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 118,436 shares of the company's stock after selling 26,175 shares during the period. PROCEPT BioRobotics accounts for 3.6% of Transatlantique Private Wealth LLC's investment portfolio, making the stock its 3rd largest holding. Transatlantique Private Wealth LLC owned 0.23% of PROCEPT BioRobotics worth $9,536,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. HighTower Advisors LLC acquired a new position in shares of PROCEPT BioRobotics in the third quarter valued at approximately $279,000. Wilmington Savings Fund Society FSB purchased a new position in PROCEPT BioRobotics in the 3rd quarter valued at $64,000. Franklin Resources Inc. increased its stake in PROCEPT BioRobotics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock valued at $64,669,000 after buying an additional 347,330 shares during the period. Lord Abbett & CO. LLC raised its position in PROCEPT BioRobotics by 45.3% during the 3rd quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company's stock worth $59,974,000 after buying an additional 233,430 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 290.2% in the 3rd quarter. Principal Financial Group Inc. now owns 68,617 shares of the company's stock worth $5,498,000 after acquiring an additional 51,030 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is owned by corporate insiders.
PROCEPT BioRobotics Price Performance
Shares of PROCEPT BioRobotics stock traded down $3.14 on Thursday, hitting $52.56. The company's stock had a trading volume of 2,968,114 shares, compared to its average volume of 802,041. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $2.88 billion, a P/E ratio of -26.95 and a beta of 1.09. The firm has a fifty day moving average price of $58.33 and a 200-day moving average price of $74.25. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. On average, equities research analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.
Analyst Ratings Changes
PRCT has been the topic of a number of recent analyst reports. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Morgan Stanley cut their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and an average price target of $91.43.
View Our Latest Report on PRCT
PROCEPT BioRobotics Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
